• Home
  •  / Intarcia Therapeutics

Intarcia Therapeutics

OverviewSuggest Edit

Intarcia Therapeutics is a biopharmaceutical company developing therapies for chronic diseases. Its flagship product, Medici Drug Delivery System, has the potential to transform the prevention and management of serious chronic diseases. The Сompany's products include OMEGA DUROS, an interferon delivery device for treating Hepatitis C and ITCA 650, a delivery device that provides type 2 diabetes patients with long-term steady-state dosing of an incretin mimetic therapy. Additionally, it develops programs for treating obesity.
TypePrivate
Founded1997
HQBoston, USMap
Websiteintarcia.com
Employee Ratings3.3More
View Jobs

Locations

Intarcia Therapeutics is headquartered in
Boston, United States

Location Map
All Locations (3)

Latest Updates

Employees (est.) (Jul 2020)275(-14%)
Cybersecurity ratingCMore

Key People/Management at Intarcia Therapeutics

Kurt Graves

Kurt Graves

Chairman, President and CEO
Bryan Roberts

Bryan Roberts

Director
Thomas Alessi

Thomas Alessi

Vice President, Development and Manufacturing
Gino Santini

Gino Santini

Director
Fred Fiedorek

Fred Fiedorek

Chief Medical Officer and Global Head of Regulatory Affairs
Nancy Thornberry

Nancy Thornberry

Director
Show more

Intarcia Therapeutics Office Locations

Intarcia Therapeutics has offices in Boston, Durham and Hayward
Boston, US (HQ)
1 Marina Park Drive
Durham, US
6 Davis Dr
Hayward, US
24650 Industrial Blvd
Show all (3)

Intarcia Therapeutics Financials and Metrics

Summary Metrics

Founding Date

1997

Intarcia Therapeutics total Funding

$1.8 b

Intarcia Therapeutics latest funding size

$73.13 m

Time since last funding

a year ago

Intarcia Therapeutics investors

GGV Capital, Marker, New Enterprise Associates, Venrock, Fidelity Investments, New Leaf Venture Partners, Baillie Gifford, Alta Partners, Farallon Capital Management, Omega Funds, RA Capital Management, Foresite Capital, The Pritzker Organization, Quadrille Capital, Kayon Partners, The Baupost Group
Intarcia Therapeutics's latest funding round in March 2019 was reported to be $73.1 m. In total, Intarcia Therapeutics has raised $1.8 b. Intarcia Therapeutics's latest valuation is reported to be $3.9 b.
View all funding rounds

Intarcia Therapeutics Revenue

Market valuation

3.9b
Show all financial metrics

Intarcia Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

76/100

Learn more about about our premium products
SecurityScorecard logo

Intarcia Therapeutics Online and Social Media Presence

Intarcia Therapeutics's Trends

Embed Graph

 Intarcia Therapeutics Frequently Asked Questions

  • When was Intarcia Therapeutics founded?

    Intarcia Therapeutics was founded in 1997.

  • Who are Intarcia Therapeutics key executives?

    Intarcia Therapeutics's key executives are Kurt Graves, Bryan Roberts and Thomas Alessi.

  • How many employees does Intarcia Therapeutics have?

    Intarcia Therapeutics has 275 employees.

  • Who are Intarcia Therapeutics competitors?

    Competitors of Intarcia Therapeutics include Marinus Pharmaceuticals, Merial and Zogenix.

  • Where is Intarcia Therapeutics headquarters?

    Intarcia Therapeutics headquarters is located at 1 Marina Park Drive, Boston.

  • Where are Intarcia Therapeutics offices?

    Intarcia Therapeutics has offices in Boston, Durham and Hayward.

  • How many offices does Intarcia Therapeutics have?

    Intarcia Therapeutics has 3 offices.